The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.
Age range
18 Years – 99 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Identify the inflammatory components by C-reactive protein
Timeframe: 24 months
Identify the inflammatory components by interleukine1
Timeframe: 24 months
Identify the inflammatory components by onterleukine6
Timeframe: 24 months
Identify the inflammatory components by interleukine10
Timeframe: 24 months
Identify the inflammatory components by Tumor Necrosis Factor
Timeframe: 24 months
Identify the inflammatory components by Transforming Growth Factor
Timeframe: 24 months